FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100707039> ?p ?o ?g. }

• W2100707039 endingPage "59" @default.
• W2100707039 startingPage "51" @default.
• W2100707039 abstract "ABSTRACT Ibrutinib is an orally administered, covalent inhibitor of Bruton's tyrosine kinase with activity in B-cell malignancies based on Phase I/II studies. We describe the design and rationale for the Phase III HELIOS trial (trial registration: EudraCT No. 2012-000600-15; UTN No. U1111-1135-3745) investigating whether ibrutinib added to bendamustine and rituximab (BR) provides benefits over BR alone in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Eligible patients must have relapsed/refractory disease measurable on CT scan and meet ≥1 International Workshop on Chronic Lymphocytic Leukemia criterion for requiring treatment; patients with del(17p) are excluded. All patients receive BR (maximum six cycles) as background therapy and are randomized 1:1 to placebo or ibrutinib 420 mg/day. Treatment with ibrutinib or placebo will start concomitantly with BR and continue until disease progression or unacceptable toxicity. The primary end point is progression-free survival. Secondary end points include safety, objective response rate, overall survival, rate of minimal residual disease-negative remissions, and patient-reported outcomes. Tumor response will be assessed using the International Workshop on Chronic Lymphocytic Leukemia guidelines." @default.
• W2100707039 created "2016-06-24" @default.
• W2100707039 creator A5002515721 @default.
• W2100707039 creator A5010286156 @default.
• W2100707039 creator A5013519562 @default.
• W2100707039 creator A5043855296 @default.
• W2100707039 creator A5049924304 @default.
• W2100707039 creator A5076077834 @default.
• W2100707039 creator A5077959613 @default.
• W2100707039 creator A5081083731 @default.
• W2100707039 creator A5081203691 @default.
• W2100707039 creator A5086151596 @default.
• W2100707039 date "2015-01-01" @default.
• W2100707039 modified "2023-10-04" @default.
• W2100707039 title "The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia" @default.
• W2100707039 cites W100713916 @default.
• W2100707039 cites W167055487 @default.
• W2100707039 cites W1976130423 @default.
• W2100707039 cites W1982411778 @default.
• W2100707039 cites W1990815726 @default.
• W2100707039 cites W2002404007 @default.
• W2100707039 cites W2011782763 @default.
• W2100707039 cites W2018946689 @default.
• W2100707039 cites W2019216438 @default.
• W2100707039 cites W2032482627 @default.
• W2100707039 cites W2043499238 @default.
• W2100707039 cites W2045399297 @default.
• W2100707039 cites W2059707463 @default.
• W2100707039 cites W2065338378 @default.
• W2100707039 cites W2071549499 @default.
• W2100707039 cites W2082312121 @default.
• W2100707039 cites W2140395974 @default.
• W2100707039 cites W2140606816 @default.
• W2100707039 cites W2142099365 @default.
• W2100707039 cites W2149360785 @default.
• W2100707039 cites W2149515595 @default.
• W2100707039 cites W2157799317 @default.
• W2100707039 cites W2163690533 @default.
• W2100707039 cites W2171771895 @default.
• W2100707039 cites W2241277596 @default.
• W2100707039 cites W2326175431 @default.
• W2100707039 doi "https://doi.org/10.2217/fon.14.119" @default.
• W2100707039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24901734" @default.
• W2100707039 hasPublicationYear "2015" @default.
• W2100707039 type Work @default.
• W2100707039 sameAs 2100707039 @default.
• W2100707039 citedByCount "18" @default.
• W2100707039 countsByYear W21007070392015 @default.
• W2100707039 countsByYear W21007070392016 @default.
• W2100707039 countsByYear W21007070392017 @default.
• W2100707039 countsByYear W21007070392018 @default.
• W2100707039 countsByYear W21007070392020 @default.
• W2100707039 countsByYear W21007070392021 @default.
• W2100707039 crossrefType "journal-article" @default.
• W2100707039 hasAuthorship W2100707039A5002515721 @default.
• W2100707039 hasAuthorship W2100707039A5010286156 @default.
• W2100707039 hasAuthorship W2100707039A5013519562 @default.
• W2100707039 hasAuthorship W2100707039A5043855296 @default.
• W2100707039 hasAuthorship W2100707039A5049924304 @default.
• W2100707039 hasAuthorship W2100707039A5076077834 @default.
• W2100707039 hasAuthorship W2100707039A5077959613 @default.
• W2100707039 hasAuthorship W2100707039A5081083731 @default.
• W2100707039 hasAuthorship W2100707039A5081203691 @default.
• W2100707039 hasAuthorship W2100707039A5086151596 @default.
• W2100707039 hasBestOaLocation W21007070391 @default.
• W2100707039 hasConcept C126322002 @default.
• W2100707039 hasConcept C142724271 @default.
• W2100707039 hasConcept C143998085 @default.
• W2100707039 hasConcept C203092338 @default.
• W2100707039 hasConcept C204787440 @default.
• W2100707039 hasConcept C27081682 @default.
• W2100707039 hasConcept C2776694085 @default.
• W2100707039 hasConcept C2776755627 @default.
• W2100707039 hasConcept C2777938653 @default.
• W2100707039 hasConcept C2778461978 @default.
• W2100707039 hasConcept C2779260929 @default.
• W2100707039 hasConcept C2779263901 @default.
• W2100707039 hasConcept C2779338263 @default.
• W2100707039 hasConcept C2779675984 @default.
• W2100707039 hasConcept C2779878957 @default.
• W2100707039 hasConcept C2780653079 @default.
• W2100707039 hasConcept C2781442060 @default.
• W2100707039 hasConcept C535046627 @default.
• W2100707039 hasConcept C71924100 @default.
• W2100707039 hasConceptScore W2100707039C126322002 @default.
• W2100707039 hasConceptScore W2100707039C142724271 @default.
• W2100707039 hasConceptScore W2100707039C143998085 @default.
• W2100707039 hasConceptScore W2100707039C203092338 @default.
• W2100707039 hasConceptScore W2100707039C204787440 @default.
• W2100707039 hasConceptScore W2100707039C27081682 @default.
• W2100707039 hasConceptScore W2100707039C2776694085 @default.
• W2100707039 hasConceptScore W2100707039C2776755627 @default.
• W2100707039 hasConceptScore W2100707039C2777938653 @default.
• W2100707039 hasConceptScore W2100707039C2778461978 @default.
• W2100707039 hasConceptScore W2100707039C2779260929 @default.
• W2100707039 hasConceptScore W2100707039C2779263901 @default.
• W2100707039 hasConceptScore W2100707039C2779338263 @default.
• W2100707039 hasConceptScore W2100707039C2779675984 @default.

• next